Uncategorized Archives - Page 133 of 134

WednesdayMar 04, 2020 11:27 am

Predictive Oncology Inc.’s (NASDAQ: POAI) Key Focus Areas of Precision Medicine, AI Listed as Top Industry Investment Trends

Precision medicine, AI among top healthcare investment trends for 2020 Predictive Oncology is data, AI-driven precision medicine company with an exclusive database of patient samples Market estimates for precision medicine expected to reach $84.6 billion by 2024 Precision medicine and artificial intelligence rank high on the list of top investment-focused healthcare trends, according to a recent Emagine article (http://nnw.fm/jKVt0). Both are key areas of focus for Predictive Oncology Inc. (NASDAQ: POAI), a leading data and artificial-intelligence-driven precision medicine company. In an arena where data is king and artificial intelligence is increasingly gravitating to the spotlight, POAI is uniquely positioned with…

MondayFeb 24, 2020 12:37 pm

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

POAI subsidiary announces new media for growing ovarian tumors in lab Using new product, TumorGenesis partners have identified 25 cell types from ovarian cancers New media available as cell-culture market expected to reach $2.3 billion by 2024 Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, along with its subsidiary TumorGenesis Inc., has announced an innovative special media for growing ovarian tumors; the companies have also selected US Biological Corporation as a manufacturer and distributor of the groundbreaking media (http://nnw.fm/2bdtl). POAI anticipates the new formulations, which will be developed in a lab, will speed discovery of biomarkers…

WednesdayFeb 19, 2020 11:41 am

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Advances Precision Therapeutics by Learning Cancer Behavior, Improving Outcomes

Predictive Oncology subsidiary TumorGenesis developing faster, less costly and more accurate PDx cancer models that better mimic patient’s tumor TumorGenesis revolutionary technology will provide pharmaceuticals with quicker, more effective drug development while significantly improving patient outcomes POAI to begin sales of TumorGenesis’ innovative culture media in the first half of 2020 TumorGenesis, a flagship subsidiary of Predictive Oncology Inc. (NASDAQ: POAI), has made concrete steps in identifying and separating cancer-related biomarkers, which is likely to speed the development of new and effective therapeutics. TumorGenesis media are specially formulated to help researchers isolate and maintain the unique histological and basic biological…

FridayJan 24, 2020 12:44 pm

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member, Audit Committee Chair

New board member, audit committee chair brings 35 years of accounting experience, mainly in management Prior worked as CFO, controller in several genomics, health companies POAI to leverage Prior’s new insights, guidance in the financial space Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, announced that Pam Prior, CPA, has been appointed to the company's Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee. Prior, 57, joins POAI’s Board of Directors with 35 years of experience in accounting, mainly in management as CFO or controller.…

FridayJan 17, 2020 12:42 pm

Predictive Oncology Inc. (NASDAQ: POAI), Leader in Precision Medicine, Committed to Playing Key Role in Decreasing Cancer Deaths

American Cancer Society annual report shows largest single-year drop in cancer deaths ever reported Doctors attribute precision medicine with playing significant role in decline POAI leading player in precision medicine, initiated groundbreaking Cancer Quest 2020 project A new American Cancer Society report bodes well for Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to help equip players in personalized medicine and drug discovery. American Cancer Society’s annual ‘Facts & Figures 2020’ report shows the largest single-year drop in cancer deaths ever reported (http://nnw.fm/twL1W). The 2.2% drop occurred from 2016 to 2017, the most recent year for…

MondayJan 13, 2020 12:11 pm

Predictive Oncology Inc.’s (NASDAQ: POAI) Disruptive Platform Overcoming Obstacles in Precision Medicine Industry

The global precision medicine market is estimated to reach $84.6 billion by 2024 Predictive Oncology is bringing cutting-edge technology to cancer research to develop highly customizable assessment methods that improve patient outcomes POAI leverages unique competitive advantage that stems from readily available access to historical data on tumor profiles and their drug responses Precision medicine, an approach that seeks to understand the genetic makeup of a patient’s tumor in order to customize a drug targeting the particular gene type for each patient, offers tremendous potential for the treatment of a number of diseases. Predictive Oncology Inc. (NASDAQ: POAI), a data…

FridayJan 10, 2020 1:09 pm

Predictive Oncology Inc. (NASDAQ: POAI) Working to Create World’s First Comprehensive, Actionable Multi-Omic Data Set for Ovarian Cancer

POAI plans to have first predictive model of ovarian cancer ready for initial commercialization in Q1 2020 First batch of 400 ovarian cancer subjects in initiative has been sequenced Groundbreaking AI-driven model of ovarian cancer will be capable of predicting tumor drug response, patient outcome Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has updated the commercialization of its pioneering CancerQuest 2020 initiative (http://nnw.fm/y6fnc). Based on the updated announcement, the company plans on having its first predictive model of ovarian cancer ready for initial commercialization in revenue-generating projects with Pharma…

WednesdayMay 29, 2019 11:08 am

Genprex Inc. (NASDAQ: GNPX) Hires Top Pharmaceutical Branding Agency to Oversee Drug Naming Process for Lead Drug Candidate

Genprex, a clinical stage gene therapy company, will be utilizing the services of a leading pharmaceutical branding agency to oversee the naming process of its lead drug candidate, Oncoprex Addison Whitney has over 28 years of experience in the market, guiding pharmaceutical companies such as Merck, Celgene and Roche through the regulatory steps involved in the name approval process Oncoprex is an innovative immunogene therapy targeting non-small cell lung cancer Genprex Inc. (NASDAQ: GNPX), a clinical stage gene therapy company, recently reported that it has retained the services of leading pharmaceutical branding agency Addison Whitney to assist with the naming…

TuesdayMay 28, 2019 12:10 pm

Genprex Inc. (NASDAQ: GNPX) Pioneering an Innovative Cancer Therapy, Preclinical Data Shows Positive Results

Gene therapy could help overcome barriers that currently stand in the way of a cure for cancer Genprex is developing innovative, gene-based approaches toward the treatment of cancer, specifically non-small cell lung cancer Clinical trials so far have yielded encouraging data regarding the efficacy and safety of the company’s product candidate, Oncoprex Gene therapy could potentially advance the creation and delivery of effective cancer treatments in the years to come. Various companies are leading the way, and pioneers such as Genprex Inc. (NASDAQ: GNPX) are pushing for the introduction of innovative and targeted therapies that have the potential to help…

WednesdayMay 08, 2019 11:24 am

Genprex Inc. (NASDAQ: GNPX) Aims to Reprogram the Course of Cancer with Gene Therapy Approach

Preclinical and clinical data indicate that Oncoprex immunogene therapy may be effective alone or in combination with targeted small molecule therapies; pre-clinical data also indicate potential effectiveness in combination with immunotherapies Lung cancer is the second-most common cancer and the leading cause of cancer deaths worldwide Genprex holds an exclusive license to more than 30 issued patents and several pending applications covering its platform technologies, including patents covering the therapeutic use of the TUSC2 tumor suppressor gene The value of the global immunotherapy drugs market is expected to surpass $385 billion by 2025, recording a CAGR of more than 14…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Predictive Oncology Inc.’s (NASDAQ: POAI) Key Focus Areas of Precision Medicine, AI Listed as Top Industry Investment Trends

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Selects Manufacturer, Distributor of Innovative Cell-Culture Media

Predictive Oncology Inc. (NASDAQ: POAI) Subsidiary Advances Precision Therapeutics by Learning Cancer Behavior, Improving Outcomes

Predictive Oncology Inc. (NASDAQ: POAI) Appoints New Board Member, Audit Committee Chair

Predictive Oncology Inc. (NASDAQ: POAI), Leader in Precision Medicine, Committed to Playing Key Role in Decreasing Cancer Deaths

Predictive Oncology Inc.’s (NASDAQ: POAI) Disruptive Platform Overcoming Obstacles in Precision Medicine Industry

Predictive Oncology Inc. (NASDAQ: POAI) Working to Create World’s First Comprehensive, Actionable Multi-Omic Data Set for Ovarian Cancer

Genprex Inc. (NASDAQ: GNPX) Hires Top Pharmaceutical Branding Agency to Oversee Drug Naming Process for Lead Drug Candidate

Genprex Inc. (NASDAQ: GNPX) Pioneering an Innovative Cancer Therapy, Preclinical Data Shows Positive Results

Genprex Inc. (NASDAQ: GNPX) Aims to Reprogram the Course of Cancer with Gene Therapy Approach

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search